Drugs / Neostigmine Methylsulfate
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | BLOXIVERZ | — | 2013-05-31 | fda.gov ↗ |
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT05289323 | Apr 2022 → Jul 2023 | intracranial hypotension | Alexandria University | Completed | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT03997006 Comparator | Jan 2019 → Jan 2020 | intracranial hypotension | Damanhour Teaching Hospital | Completed | No outcome recorded |
| Phase 4 | NCT03587441 Comparator | Aug 2018 → Feb 2019 | intracranial hypotension | Fayoum University Hospital | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Neostigmine Methylsulfate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03997006 ↗ |
| Action | Inhibit | “reversibly inhibits the enzyme Acetylcholine esterase (AChE)” NCT03587441 ↗ |
| Modality | Small molecule | “Neostigmine methylsulfate is a synthetic carbamic acid ester” NCT03587441 ↗ |
| Route | Intrathecal | “Neostigmine Methylsulfate intrathecal” NCT03587441 ↗ |